TERT (Telomerase Reverse Transcriptase)

P1/2, N=35, Recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: May 2027 --> Mar 2028 | Trial primary completion date: May 2027 --> Mar 2028

The oncogenic pattern of MUP showed a UV signature suggesting an origin in sun-exposed localisations. OS of MUP is comparable to melanoma of known cutaneous primary.

Synchronous two-nodule HCC without satellite nodules represents a prognostically favourable subgroup distinct from satellite-nodule HCC. A simplified morphology-based stratification may better reflect clinical outcomes in multifocal HCC.

Toripalimab demonstrated promising activity and manageable safety in pretreated mUTUC. High TMB was associated with numerically improved outcomes, suggesting its potential role as an exploratory biomarker for response to PD-1 blockade in this population.

In addition, HS1002 increased the production of granzyme B and IFN-γ in CD8+ T cells in MC38 syngeneic mice. These findings demonstrate that HS1002 suppresses prostate cancer cell growth and induces anticancer immunity, suggesting its potential as a novel therapeutic agent against prostate cancer.

By integrating germline (GWAS-based) and somatic evidence, this study provides a comprehensive view of HCC pathogenesis. This integrated strategy successfully identified a core set of genes and proteins with potential causal links to HCC, elucidating their functional convergence in cancer biology. These findings offer novel molecular insights and candidate targets for precise diagnosis, prognostic assessment, and targeted therapy of HCC, laying a solid foundation for future translational research.

We observed no evidence of established stress-induced premature or replicative senescence in drug-resistant epilepsy patients. However, elevated proinflammatory cytokines and high p21/p16 expression in the drug-resistant group may suggest ongoing seizures cause cellular stress which could increase susceptibility to senescence in drug-resistant pediatric epilepsy patients over time.

This approach may facilitate personalized treatment planning and address limitations of invasive tissue-based diagnostics. Further validation with multi-center data is warranted to enhance clinical applicability.

In summary, we report 7 new BRAF fusions in PTC BRAF V600E-WT. Additional clinical research is needed to elucidate the behavior of BRAF fusion-driven thyroid carcinomas and the therapeutic utility of MAPK pathway inhibitors.

Pre-analytical confounders (blood collection tubes, hemolysis, storage conditions), platform-dependent analytical variation, lack of external quality assessment programs, and scarcity of demonstrations of clinical utility in prospective biomarker-directed research are critical translational barriers. Such standardized handling of specimens, commutable reference materials, and reporting of the characteristics of analytical performance would be clearly linked to effective clinical use in accordance with the requirements of laboratory medicine.

We have provided fresh insights into the crosstalk between telomere and mitochondrial biology in CRC precursors. These findings hold promise in understanding adenoma formation and CRC progression, as mtDNA-CN elevation and its association with TL were specific to precancerous lesions and were lost with progression to tumor.